natgillin/translations-raw huggingface dataset:
What Rivastigmine 3M Health Care Ltd. is and what it is used for What you need to know before you use Rivastigmine 3M Health Care Ltd. How to use Rivastigmine 3M Health Care Ltd. 
Kaj je zdravilo Rivastigmin 3M Health Care Ltd. in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Rivastigmin 3M Health Care Ltd. Kako uporabljati zdravilo Rivastigmin 3M Health Care Ltd.
The efficacy of rivastigmine transdermal patches in patients with Alzheimer's dementia has been demonstrated in a 24-week double-blind, placebo-controlled core study and its open-label extension phase and in a 48-week double-blind comparator study. 
Učinkovitost transdermalnih obližev z rivastigminom pri bolnikih z Alzheimerjevo demenco so dokazali v 24-tedenski dvojno slepi, s placebom kontrolirani osnovni študiji in njenem odprtem podaljšku ter v 48-tedenski dvojno slepi primerjalni študiji.
Less NAP226-90 is formed following application of the transdermal patch, presumably because of the lack of presystemic (hepatic first pass) metabolism, in contrast to oral administration. 
Po aplikaciji transdermalnega obliža je nastajalo manj NAP226-90, verjetno zaradi odsotnosti predsistemske presnove (učinka prvega prehoda skozi jetra) za razliko od peroralne aplikacije.
Transdermal patches should be applied once a day to clean, dry, hairless, intact healthy skin on the upper or lower back, upper arm or chest, in a place which will not be rubbed by tight clothing. 
Transdermalne obliže je treba enkrat na dan namestiti na čist, suh, neporaščen in nepoškodovan predel kože na zgornjem ali spodnjem delu hrbta, na nadlakti ali na prsih, na mesto, ki ga ne drgnejo oblačila.
At least 4 points improvement on ADAS-Cog with no worsening on ADCSCGIC and ADCS-ADL 
Izboljšanje na ADAS-Cog za vsaj 4 točke brez poslabšanja pri ADCS-CGIC in ADCSADL
left upper chest or right upper chest (avoid breast) 
• levi zgornji del prsi ali desni zgornji del prsi (ne na dojko)
Name and address of the manufacturer responsible for batch release 
Ime in naslov izdelovalcev, odgovornih za sproščanje serije
If you use more Rivastigmine 3M Health Care Ltd. than you should If you accidentally apply more than one patch, remove all the patches from your skin, then inform your doctor that you have accidentally applied more than one patch. 
Če ste uporabili večji odmerek zdravila Rivastigmin 3M Health Care Ltd. , kot bi smeli Če ste nehote namestili več kot en obliž, odstranite s kože vse obliže in obvestite zdravnika, da ste nehote namestili več kot en obliž.
You may have side effects more often when you start your medicine or when your dose is increased. 
Neželeni učinki bodo morda pogostejši na začetku uporabe zdravila in ob zviševanju odmerka.
Some people who have accidentally taken too much Rivastigmine 3M Health Care Ltd. have experienced feeling sick (nausea), being sick (vomiting), diarrhoea, high blood pressure and hallucinations. 
Pri nekaterih ljudeh, ki so nehote vzeli preveč zdravila Rivastigmin 3M Health Care Ltd., je prišlo do navzee (slabosti s siljenjem na bruhanje), bruhanja, driske, visokega krvnega tlaka in halucinacij.
Concomitant administration of rivastigmine with commonly prescribed medicinal products, such as antacids, antiemetics, antidiabetics, centrally acting antihypertensives, beta blockers, calcium channel blockers, inotropic agents, antianginals, non-steroidal anti-inflammatory agents, oestrogens, analgesics, benzodiazepines and antihistamines, was not associated with an alteration in the kinetics of rivastigmine or an increased risk of clinically relevant untoward effects. 
Sočasna uporaba rivastigmina s katerim od pogosto predpisanih zdravil, kot so antacidi, antiemetiki, antidiabetiki, antihipertenzivi z osrednjim delovanjem, zaviralci adrenergičnih receptorjev beta, zaviralci kalcijevih kanalčkov, inotropne učinkovine, antianginiki, nesteroidne protivnetne učinkovine, estrogeni, analgetiki, benzodiazepini in antihistaminiki, ni bila povezana s spremembami kinetike rivastigmina ali s povečanim tveganjem za klinično pomembne neželene učinke.
The exposure to rivastigmine and its metabolites was approximately equivalent to human exposure with highest doses of rivastigmine capsules and transdermal patches. 
Izpostavljenost rivastigminu in njegovim presnovkom je bila približno enakovredna izpostavljenosti pri ljudeh pri uporabi kapsul in transdermalnih obližev z največjimi odmerki.
The use of this medicinal product is contraindicated in patients with known hypersensitivity to the active substance rivastigmine, to other carbamate derivatives or to any of the excipients listed in section 6.1. 
Uporaba tega zdravila je kontraindicirana pri bolnikih, ki imajo ugotovljeno preobčutljivost na zdravilno učinkovino rivastigmin, druge derivate karbamata ali katero koli pomožno snov, navedeno v
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ
left upper back or right upper back left lower back or right lower back 
• levi spodnji del hrbta ali desni zgornji del hrbta
INSTRUCTIONS ON USE 
Način uporabe
It is possible that some patients sensitised to rivastigmine by exposure to rivastigmine patch may not be able to take rivastigmine in any form. 
Lahko se zgodi, da nekateri bolniki, pri katerih je zaradi uporabe rivastigmina v transdermalnem obližu prišlo do senzitizacije na rivastigmin, ne bi mogli več uporabljati rivastigmina v nobeni obliki.
Application site reactions were mostly mild to moderate in severity and were rated as severe in less than 2% of patients. 
Reakcije na mestu aplikacije so bile večinoma blago do zmerno izražene, kot hude jih je opredelilo manj kot 2 % bolnikov.
One transdermal patch is sealed in one pouch. 
V eni vrečki je zaprt en transdermalni obliž.
The 24-week results for the three assessment tools are summarised in Table 2. 
24-tedenski rezultati teh treh metod ocenjevanja so zbrani v Preglednici 2.
As a cholinesterase inhibitor, rivastigmine may exaggerate the effects of succinylcholine-type muscle relaxants during anaesthesia. 
Ker je rivastigmin zaviralec holinesteraze, lahko močno poveča učinke mišičnih relaksantov tipa sukcinilholina med anestezijo.
No effects on fertility or embryofoetal development were observed in rats and rabbits, except at doses related to maternal toxicity. 
Pri podganah in kuncih niso opazili nikakršnih učinkov na plodnost ali razvoj zarodka ali ploda, razen v odmerkih, povezanih s toksičnostjo za mater.
The typical symptoms reported among these cases are similar to those seen with cases of overdose associated with rivastigmine oral formulations. 
Značilni simptomi, o katerih so poročali pri teh primerih, so podobni kot pri primerih prevelikega odmerjanja peroralnih oblik z rivastigminom.
If this applies to you, tell your doctor and do not apply Rivastigmine 3M Health Care Ltd. transdermal patches. 
Če kaj od navedenega velja za vas, povejte svojemu zdravniku in ne uporabljajte transdermalnih obližev Rivastigmin 3M Health Care Ltd..
- After removing a patch, fold it in half with the sticky sides on the inside and press them together. 
- Po odstranitvi obliža s kože ga prepognite na pol z lepljivo stranjo navznoter in stisnite.
Caution is recommended when selecting anaesthetic agents. 
Pri izbiri sredstva za anestezijo je priporočena previdnost.
- Do not expose the patch to any external heat sources (e.g. excessive sunlight, saunas, solarium) 
- Obliža ne izpostavljajte zunanjim virom toplote (na primer prekomernemu sončenju, savni,
Patients who show signs or symptoms of dehydration resulting from prolonged vomiting or diarrhoea can be managed with intravenous fluids and dose reduction or discontinuation if recognised and treated promptly. 
Bolnike z znaki ali s simptomi dehidracije zaradi dolgotrajnega bruhanja ali driske je v primeru prepoznavanja stanja in takojšnjega ukrepanja mogoče zdraviti z intravenskim nadomeščanjem tekočin in z znižanjem ali prekinitvijo odmerjanja.
Specific dermal studies in pregnant animals have not been conducted. 
Posebnih kožnih študij na brejih živalih niso opravili.
It is not recommended to apply the transdermal patch to the thigh or to the abdomen due to decreased bioavailability of rivastigmine observed when the transdermal patch is applied to these areas of the body. 
Na stegno ali na trebuh transdermalnega obliža ni priporočljivo nameščati, ker so opazili zmanjšano biološko uporabnost rivastigmina v primerih namestitve na te predele.
Rectangular patches, approximately 2.5 cm by 1.8 cm with rounded corners. 
Pravokotni, približno 2,5 cm krat 1,8 cm veliki obliži z zaobljenimi vogali.
Description of selected adverse reactions 
Opis izbranih neželenih dogodkov
Oral studies in pregnant rats and rabbits gave no indication of teratogenic potential on the part of rivastigmine. 
V peroralnih študijah na brejih podganah in kuncih se niso pokazali nikakršni znaki teratogenega potenciala rivastigmina.
Otherwise treatment should be re-initiated with 4.6 mg/24 h. 
V nasprotnem primeru je treba zdravljenje ponovno začeti z odmerkom 4,6 mg/24 h.
Total plasma clearance of rivastigmine was approximately 130 litres/h after a 0.2 mg intravenous dose and decreased to 70 litres/h after a 2.7 mg intravenous dose, which is consistent with the non-linear, over-proportional pharmacokinetics of rivastigmine due to saturation of its elimination. 
Celotni plazemski očistek rivastigmina je bil po intravenskem odmerku 0,2 mg približno 130 l/h, po intravenskem odmerku 2,7 mg pa se je zmanjšal na 70 l/h, kar je v skladu z nelinerano nesorazmerno farmakokinetiko rivastigmina zaradi saturacije njegovega izločanja.
By blocking these enzymes, Rivastigmine 3M Health Care Ltd. allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer's disease. 
Zdravilo Rivastigmin 3M Health Care Ltd. z zaviranjem navedenih encimov omogoča zvišanje koncentracije acetilholina v možganih in s tem pomaga pri zmanjševanju simptomov Alzheimerjeve bolezni.
It is recommended to apply the first transdermal patch on the day following the last oral dose. 
Prvi transdermalni obliž je priporočljivo namestiti na dan, ki sledi dnevu zadnjega peroralnega
- The patch should not be exposed to any external heat sources (e.g. excessive sunlight, saunas, 
- Obliža se ne sme izpostavljati zunanjim virom toplote (na primer prekomernemu sončenju,
Patients who develop application site reactions suggestive of allergic contact dermatitis to rivastigmine patch and who still require rivastigmine treatment should only be switched to oral rivastigmine after negative allergy testing and under close medical supervision. 
Bolniki, pri katerih reakcija na mestu apliciranja kaže, da bi lahko šlo za alergijski kontaktni dermatitis na rivastigmin iz transdermalnega obliža in kljub temu potrebujejo zdravljenje z rivastigminom, lahko preidejo na zdravljenje s peroralno obliko rivastigmina samo v primeru, da je pri njih izvid testiranja na alergijo negativen, nato pa lahko rivastigmin jemljejo le pod skrbnim zdravniškim nadzorom.
As rivastigmine has a plasma half-life of about 3.4 hours and a duration of acetylcholinesterase inhibition of about 9 hours, it is recommended that in cases of asymptomatic overdose all Rivastigmine 3M Health Care Ltd. transdermal patches should be removed immediately and no further transdermal patch should be applied for the next 24 hours. 
Ker ima rivastigmin plazemski razpolovni čas okrog 3,4 ure in trajanje zaviranja acetilholinesteraze okrog 9 ur, v primeru asimptomatičnega prevelikega odmerka priporočamo takojšnjo odstranitev vseh transdermalnih obližev Rivastigmin 3M Health Care Ltd.. Bolniku se v naslednjih 24 urah ne sme namestiti novih transdermalnih obližev.
In peri/postnatal studies in rats, an increased gestation time was observed. 
V perinatalnih in postnatalnih študijah pri podganah so opazili podaljšano obdobje brejosti.
In overdose accompanied by severe nausea and vomiting, the use of antiemetics should be considered. 
Pri prevelikem odmerku, ki ga spremljata huda navzea in bruhanje, pridejo v poštev antiemetiki.
Elimination was absorption rate limited (flip-flop kinetics), which explains the longer t½ after transdermal patch (3.4 h) versus oral or intravenous administrations (1.4 to 1.7 h). 
Izločanje je omejeno s hitrostjo absorpcije (flipflop učinek), kar pojasnjuje daljši t½ pri uporabi transdermalnih obližev (3,4 ure) v primerjavi s peroralnim ali intravenskim odmerjanjem (1,4 do 1,7 ure).
The increase in prothrombin time induced by warfarin is not affected by administration of oral rivastigmine. 
Na podaljšanje protrombinskega časa, ki ga povzroči varfarin, dajanje peroralnega rivastigmina ne vpliva.
Negative ADAS-Cog changes indicate improvement. 
Negativna sprememba na ADAS-Cog lestvici pomeni izboljšanje.
*A marketing authorisation for Rivastigmine 3M Health Care Ltd. 13.3 mg/24 h transdermal patch is currently not available, this presentation may although be available from other marketing authorisation holders. 
*Dovoljenje za promet za zdravilo Rivastigmin 3M Health Care Ltd. 13,3 mg/24 h transdermalni obliž trenutno ni na razpolago, čeprav obstaja možnost, da imajo to jakost na razpolago drugi imetniki
The transdermal patch should not be applied to skin that is red, irritated or cut. 
Transdermalnega obliža se ne sme namestiti na pordelo, razdraženo ali porezano/spraskano kožo.
Therefore, the patient/caregiver should avoid contact with the eyes after handling of the patch (see section 4.4). 
Zato se bolniki/negovalci ne smejo dotikati oči po rokovanju z obližem (glejte poglavje 4.4).
Table 1 displays the adverse reactions reported in 854 patients with Alzheimer's dementia treated in randomised, double-blind, placebo and active-controlled clinical studies with rivastigmine transdermal patches for a duration of 24-48 weeks and from post-marketing data. 
V Preglednici 1 so navedeni neželeni učinki o katerih so poročali pri 854 bolnikih z Alzheimerjevo demenco, zdravljenih v okviru randomiziranih dvojno slepih, s placebom in aktivno kontroliranih kliničnih študij s transdermalnimi obliži z rivastigminom, ki so trajale od 24 do 48 tednov, in neželeni učinki po podatkih iz obdobja trženja zdravila.
- The patch should not be cut into pieces. 
- Obliža se ne sme rezati na manjše dele.
Allergic contact dermatitis should be suspected if application site reactions spread beyond the patch size, if there is evidence of a more intense local reaction (e.g. increasing erythema, oedema, papules, vesicles) and if symptoms do not significantly improve within 48 hours after patch removal. 
Na alergijski kontaktni dermatitis je treba pomisliti v primeru, da se reakcija na mestu apliciranja razširi preko površine, ki jo pokriva obliž, in je mogoče opaziti večjo izraženost lokalne reakcije (na primer vse bolj izražen eritem, oteklino, rdečino, papularen ali vezikulozen izpuščaj), simptomi pa se v 48 urah po odstranitvi obliža bistveno ne izboljšajo.
After the peak, plasma concentrations slowly decrease over the remainder of the 24-hour period of application. 
Cmax doseže po 10-16 urah, nato koncentracija v plazmi počasi upada v preostalem času 24-urnega obdobja aplikacije.
Rivastigmine belongs to a class of substances called cholinesterase inhibitors. 
Rivastigmin sodi v skupino učinkovin, ki jih imenujemo zaviralci holinesteraze.
The DLSM, 95% CI, and p-value are based on an ANCOVA (analysis of covariance) model adjusted for country and baseline ADAS-cog score. 
Vrednosti razlik po metodi najmanjših kvadratov (DLSM), 95 % IZ in vrednosti p temeljijo na modelu ANCOVA (analizi kovariance) s prilagajanjem na državo in izhodiščno oceno pri lestvici ADAS-cog * p<0,05
In healthy young men, an oral 3 mg dose decreases acetylcholinesterase (AChE) activity in CSF by approximately 40% within the first 1.5 hours after administration. 
Pri zdravih mladih moških peroralni odmerek 3 mg zmanjša aktivnost acetilholinesteraze (AChE) v cerebrospinalni tekočini (CSF) za približno 40 % v poldrugi uri po zaužitju.
- Do not use this medicine if you see that the patch is damaged or shows signs of tampering. 
- Ne uporabljajte obliža, če je ovojnina poškodovana ali opazite, da je bila že odprta.
- Do not use this medicine after the expiry date, which is stated on the carton and pouch after 
- Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in vrečki poleg oznake Uporabno do/EXP.
Clinically relevant improvement was defined a priori as at least 4-point improvement on the ADAS-Cog, no worsening on the ADCS-CGIC, and no worsening on the ADCS-ADL. 
Klinično pomembno izboljšanje je bilo opredeljeno a priori kot izboljšanje na ADAS-Cog lestvici za vsaj 4 točke, brez poslabšanja v razvrstitvi ADCS-CGIC in brez poslabšanja
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN 
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
Initial dose Treatment is started with 4.6 mg/24 h. 
Začetni odmerek Zdravljenje se začne z odmerkom 4,6 mg/24 h.
No pharmacokinetic interaction was observed between oral rivastigmine and digoxin, warfarin, diazepam or fluoxetine in studies in healthy volunteers. 
Med peroralnim rivastigminom in digoksinom, varfarinom, diazepamom ali fluoksetinom v študijah na zdravih prostovoljcih niso opazili farmakokinetičnega medsebojnega delovanja.
According to its metabolism, metabolic interactions with other medicinal products appear unlikely, although rivastigmine may inhibit the butyrylcholinesterase mediated metabolism of other substances. 
Glede na njegovo presnovo se zdi presnovno medsebojno delovanje z drugimi zdravili malo verjetno, čeprav lahko rivastigmin zavre presnovo drugih učinkovin, v katero je vključena butirilholinesteraza.
Return the used patch to its sachet and dispose of it in such a way that children cannot handle it. Do not touch your eyes with your fingers and wash your hands with soap and water after removing the patch. 
Po odstranjevanju obliža se s prsti ne dotikajte oči, roke si umijte z vodo in milom.
They may experience more adverse reactions and may be more likely to discontinue due to adverse reactions. 
Pri teh bolnikih je lahko število neželenih učinkov večje, obstaja pa tudi večja verjetnost, da bodo zaradi neželenih učinkov zdravljenje prekinili.
The results for clinically relevant responders from the 24-week placebo-controlled study are provided in Table 3. 
Rezultati bolnikov s klinično pomembnim odzivom iz 24-tedenske s placebom kontrolirane študije so navedeni v Preglednici 3.
In animals, rivastigmine crosses the placenta and is excreted into milk. 
Pri živalih rivastigmin prehaja skozi posteljico in se izloča v mleko.
For patients starting treatment for the first time and for patients restarting Rivastigmine 3M Health Care Ltd. after treatment interruption, please begin with the second picture. 
Bolniki, ki si prvič nameščate obliž ali ponovno začenjate z uporabo zdravila Rivastigmin 3M Health Care Ltd. po prekinitvi zdravljenja, lahko začnete z naslednjim korakom.
Rivastigmine 3M Health Care Ltd. might interfere with anticholinergic medicines some of which are medicines used to relieve stomach cramps or spasms (e.g. dicyclomine), to treat Parkinson's disease (e.g. amantadine) or to prevent motion sickness (e.g. diphenhydramine, scopolamine or meclizine). 
Zdravilo Rivastigmin 3M Health Care Ltd. lahko vpliva na antiholinergična zdravila, med katera sodijo zdravila, ki se uporabljajo za lajšanje želodčnih krčev (npr. diciklomin), za zdravljenje Parkinsonove bolezni (npr. amantadin) ali za preprečevanje potovalne slabosti (npr. difenhidramin,
Can you wear your Rivastigmine 3M Health Care Ltd. transdermal patch when you are bathing, swimming, or in the sun? 
Se sme transdermalni obliž Rivastigmin 3M Health Care Ltd. nositi med kopanjem in plavanjem ter na soncu?
- Patients with body weight below 50 kg: Particular caution should be exercised in titrating patients with body weight below 50 kg above the recommended effective dose of 9.5 mg/24 h (see section 4.4). 
- Bolniki s telesno maso manjšo od 50 kg: Pri bolnikih s telesno maso manjšo od 50 kg je pri zviševanju odmerka nad priporočeni učinkoviti odmerek 9,5 mg/24 h potrebna posebna previdnost (glejte poglavje 4.4).
Therefore, women on rivastigmine should not breast-feed. 
Zato naj matere, ki jemljejo rivastigmin, ne dojijo.
However, due to increased exposure in these populations as observed with the oral forms, dosing recommendations to titrate according to individual tolerability should be closely followed as patients with clinically significant hepatic impairment might experience more adverse reactions. 
Vendar se je treba zaradi povečane izpostavljenosti zdravilu pri teh populacijah, kar so opažali pri uporabi peroralnih oblik zdravila, natančno ravnati po priporočilih, naj se odmerjanje titrira glede na individualno prenašanje, saj je pri bolnikih s klinično pomembno okvaro jeter lahko število neželenih učinkov večje.
When doses higher than 13.3 mg/24 h were used in the above-mentioned placebo-controlled study, insomnia and cardiac failure were observed more frequently than with 13.3 mg/24 h or placebo, suggesting a dose effect relationship. 
Kadar so v eni od zgoraj navedenih študij, s placebom kontrolirani študiji, uporabljali odmerke, ki so bili višji od 13,3 mg/24 h, so opažali nespečnost in popuščanje srca pogosteje kot pri odmerku 13,3 mg/24 h ali pri placebu, kar nakazuje odvisnost od velikosti odmerka.
Absorption of rivastigmine from rivastigmine transdermal patches is slow. 
Rivastigmin se iz transdermalnih obližev z rivastigminom absorbira počasi.
Your doctor will tell you which Rivastigmine 3M Health Care Ltd. transdermal patch is most suitable for you. 
Zdravnik vam bo povedal, kateri transdermalni obliž Rivastigmin 3M Health Care Ltd. je za vas najbolj primeren.
If you have to undergo surgery whilst using Rivastigmine 3M Health Care Ltd. transdermal patches, tell your doctor that you are using them because they may exaggerate the effects of some muscle relaxants during anaesthesia. 
Če morate v času uporabe transdermalnih obližev Rivastigmin 3M Health Care Ltd. na kirurški poseg, morate obvestiti zdravnika, da jih uporabljate, ker lahko med anestezijo povečajo učinke nekaterih
Not known (frequency cannot be estimated from the available data) - Allergic reaction where the patch was used, such as blisters or inflamed skin - The signs of Parkinson's disease get worse - such as tremor, stiffness and shuffling - Inflammation of the pancreas - signs include serious upper stomach pain, often with feeling sick 
Pogostnost neznana (je ni mogoče oceniti iz razpoložljivih podatkov) - alergijske reakcije na mestu uporabe obliža, kot je pojav mehurjev ali vnete kože - poslabšanje znakov Parkinsonove bolezni - kot so tremor, okorelost in težave pri hoji - vnetje trebušne slinavke - med znaki so hude bolečine v zgornjem delu trebuha, pogosto skupaj z občutkom slabosti (navzeo) ali bruhanjem
4.5 Interaction with other medicinal products and other forms of interaction No specific interaction studies have been performed with Rivastigmine 3M Health Care Ltd. transdermal patches. 
4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij S transdermalnimi obliži Rivastigmin 3M Health Care Ltd. niso izvedli specifičnih študij medsebojnega
The study was designed to compare the efficacy of the 13.3 mg/24 h transdermal patch against the 9.5 mg/24 h transdermal patch during a 48-week double-blind treatment phase in Alzheimer's disease patients who demonstrated functional and cognitive decline after an initial 24-48 week openlabel treatment phase while on a maintenance dose of 9.5 mg/24 h transdermal patch. 
.Študija je bila zasnovana za primerjavo učinkovitosti transdermalnega obliža 13,3 mg/24 h z učinkovitostjo transdermalnega obliža 9,5 mg/24 h v 48-tedenskem obdobju dvojno slepega zdravljenja bolnikov z Alzheimerjevo demenco, pri katerih je po začetnem 24-48-tedenskem obdobju odprtega zdravljenja z vzdrževalnim odmerkom z uporabo transdermalnega obliža 9,5 mg/24 h prišlo do funkcionalnega in kognitivnega upada.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu. 
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila